Abstract

Poster session 1, September 21, 2022, 12:30 PM - 1:30 PMAimThis study was performed to evaluate the clinical, epidemiological, and antifungal susceptibility profile of Fusarium species from clinical cases.MethodsThis study was conducted over a period of 14 years in a tertiary hospital in North India, 84 clinical isolates of Fusarium species isolated from various clinical samples like corneal scrapings, nail, tissue, and blood. The isolates were characterized phenotypically, and antifungal susceptibility testing was performed by broth microdilution method as per document CLSI M38-A3.ResultsOn phenotypic identification, 69.04% were Fusarium solani sensu stricto, followed by Fusarium oxysporum (22.61%), Fusarium dimerum (8.33%) and Fusarium incarnatum (1.19%). The infection spectrum of Fusarium spp. was onychomycosis (54.76%), keratomycosis (19.04%), fusariosis (15.47%), white grain mycetoma (3.57%), burn wound infection (3.57%), hyalohyphomycosis (3.57%). In all 92.85% isolates were susceptible to amphotericin B (0.125-1 μg/ml). For voriconazole, 70.23% strains had MIC ranging between 0.5-1 μg/ml, while 29.76% had MIC >4 μg/ml. High MICs were found to itraconazole (>16 μg/ml), caspofungin (>16 μg/ml) and fluconazole (>64 μg/ml).Conclusion Fusarium solani is the most common species isolated. Fusarium spp. causes a broad spectrum of infections in humans including superficial, locally invasive, and disseminated infections. The clinical form of Fusarium species infections depends largely on the immune status of the host and the portal of entry of pathogen. Antifungal susceptibility testing is recommended owing to the variable susceptibility pattern of Fusarium spp. Large-scale studies are required to know the exact epidemiological, clinical factors, and antifungal susceptibility patterns of Fusarium infections.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.